<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20231031059918N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2023-11-13</date_registration>
      <primary_sponsor>Yazd University of Medical Sciences</primary_sponsor>
      <public_title>Comparing the effectiveness of Ciprofloxacin, Ceftriaxone, and Gentamicin for preventing bacteriuria after transurethral lithotripsy (TUL)</public_title>
      <acronym></acronym>
      <scientific_title>Comparing the effectiveness of Ciprofloxacin, Ceftriaxone, and Gentamicin for preventing bacteriuria after transurethral lithotripsy (TUL)</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2023-11-25</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>264</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/73638</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Other, Purpose: Treatment, Randomization description: Allocating the samples to the intervention groups will be through the creation of a random sequence using the permutation block method using the Random Allocation software and a computer-generated list of random numbers. Therefore it is done by a person not involved in the study and randomized codes are kept in sealed envelopes and open at the time of patient recruitment , Blinding description: Participants will not know which of the 3 antibiotics they will receive. However, Principal investigator, health care personnel and data collection officer will be informed.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Comparing the effectiveness of ciprofloxacin, ceftriaxone, and gentamicin for preventing bacteriuria after transurethral lithotripsy.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: 88 patients use 1 g ceftriaxone 30 minutes before surgery. Intervention 2: Intervention group: 88 patients are injected with 400mg ciprofloxacin 30 minutes before surgery. Intervention 3: Intervention group: 88 patients are injected 2 mg/kg gentamicin 30 minutes before surgery.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
All data is potentially shareable after de-identifying individuals

When:
The access period starts after the results are printed

To whom:
all of the people

Conditions:
There is no special condition

Where to obtain:
My postal address for correspondence, or email address, phone numbers

How to obtain:
There is no specific process

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>nazanin Akhavan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>City of Yazd, Jomhouri Boulevard, Alley 56, Seventh Alley, Second Dead End, Second House</address>
        <city>yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8917956195</zip>
        <telephone>+98 35 3523 6600</telephone>
        <email>nazanin1379akhavan@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Nazanin Akhavan</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Second house , second dead end ,seventh alley , alley 56 , jomhouri boulevard , city of yazd</address>
        <city>Yazd</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>8917956195</zip>
        <telephone>+98 35 3523 6600</telephone>
        <email>nazanin1379akhavan@gmail.com</email>
        <affiliation>Yazd University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with middle and distal ureteral calculi with negetive urine culture that are going to undergo TUL (the maximum diameter of the stone is &lt;2 cm)
Age 18 to 65 years old.</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>65 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Asymptomatic patients with colony count ≥ 10 5  CFU/mL or a symptomatic UTI with colony count ≥  10 3  CFU/mL
Patients with any catheter.
Patients with preoperative fever (body temperature ≥ 38°C)
Patients with a history of diabetes.
Patients with immunocompromised diseases or using immunosuppressive drugs
Patients with abnormal renal function
Patients who have received antimicrobial treatment within two weeks before enrollment
Pregnant or breastfeeding women
Patients who are allergic to our research drugs.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code></hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword></hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: 88 patients use 1 g ceftriaxone 30 minutes before surgery</i_keyword>
      <i_keyword>Intervention group: 88 patients are injected with 400mg ciprofloxacin 30 minutes before surgery.</i_keyword>
      <i_keyword>Intervention group: 88 patients are injected 2 mg/kg gentamicin 30 minutes before surgery.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Significant bacteriuria was defined asymptomatic patients with colony count ≥ 10 5  CFU/mL or a symptomatic UTI with colony count ≥  10 3  CFU/mL. Timepoint: After 48 hour of surgery, routine urine tests and urine bacterial cultures,  will be recorded. Method of measurement: Routine urine tests and urine bacteria culture are done in the Rahnemoun hospital laboratory.</prim_outcome>
      <prim_outcome>Febrile urinary tract infection (fUTI) is defined as a body temperature of 38.5 C accompanying urinary tract infection after surgery. Timepoint: After 48 hour of surgery. Method of measurement: body temperature by thermometer will be recorded.</prim_outcome>
      <prim_outcome>•	SIRS criteria defined by: WBC &lt; 4000 or &gt; 12000 , heart rate &gt; 90 per minute , temperature &lt; 36 C or &gt; 38 C , respiratory rate &gt;20 or pCO2 &lt; 32 . (Presence of two or more of these criteria is accepted as SIRS.). Timepoint: After 48 hour of surgery. Method of measurement: Routine urine tests and urine bacteria culture are done in the Rahnemoun hospital laboratory.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Yazd University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2023-11-08</approval_date>
        <contact_name>Faculty of Medicine - Shahid Sadougi University of Medical Sciences, Yazd (Research Ethics Committee</contact_name>
        <contact_address>Jomhouri Boulevard, Alley 56, Seventh Alley, Second Dead End, Second House yazd Yazd Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
